2019年11月18日 · Of those, 3 were CD19 dim or negative before CAR T-cell therapy, and 3 received prior blinatumomab with overlap of both in 1 patient (HP-34). Three CD19 dim/negative patients of the 11 nonresponders was a higher rate than 6 CD19 dim patients of 59 achieving remission, but the difference was not significant (Fisher’s exact test; P = .14).

2022年3月25日 · CD19-dim（定义为白血病细胞上的CD19表达低于非恶性B细胞）更常见于既往接受过blinatumomab治疗的患者，且CD19-dim患者在接受抗CD19 CAR-T治疗后的结局不佳（60.7%的患者缺乏缓解或疾病复发）。在既往接受过靶向CD22治疗（如inotuzumab ozogamicin）或抗CD22 CAR-T治疗的患者中 ...

The leukemic PCs often have lymphoplasmacytoid morphology and may even variably express CD19 with dim surface light chain expression in a subset of cases, mimicking B-cell lymphoma with marked plasmacytic differentiation 21, 22. The correct diagnosis can often be ascertained by the overall aberrant phenotypic profile, dim or/and negative for ...

2004年12月10日 · Therefore, the expected sensitivity for identifying a CD19-dim malignant B-cell lymphoma cell using CD19 expression alone to identify the neoplastic cells is slightly higher than 0.04%. Some of the normal CD19-dim events that lack surface light chain and are likely granulocytic or monocytic elements within the lymphocyte gate or T or natural ...

2019年11月26日 · The presence of dim CD19 or rare CD19- events by flow cytometry did not predict nonresponse or recurrence after CAR T-cell therapy. However, prior therapy with the CD19-directed, bispecific T-cell engager blinatumomab was associated with a significantly higher rate of failure to achieve MRD- remission or subsequent loss of remission with ...

CLL has a characteristic immunophenotype, expressing CD5, CD19, dim CD20, dim CD22, CD23, bright CD43, dim CD45, dim to negative CD79b, dim CD81, CD200, and dim monoclonal surface immunoglobulin. This characteristic immunophenotype allows a definitive diagnosis and the ruling out of another leukemia or lymphoma. Flow cytometry also provides ...

The CD19+CD56+ co-expressing cells (CD19+NK cells) are in green and both the FSC and SSC characteristics and CD19/CD56 dim pattern are shown. B- B cell associated antigens in CD19+NK cells identified by its CD19 dim expression (arrow), both specific (B1) and other associated B cell antigens (B2) are shown in a representative case.

However, this approach is not optimal in the diagnosis and follow-up of CD19 negative or dim B-ALLs. Though CD19 negative B-ALLs are rare, in the current era of CD19 targeted immuno-therapy, CD19 negative B-ALL relapses are frequent. We have presented our cohort of 14 de novo CD19 negative and dim B-ALLs and have highlighted the difficulties ...

2018年10月1日 · The CD19 status of these 32 patients at the time of relapse was: 14 CD19 –, 3 CD19 +, 1 CD19 dim, 5 CD19 +/−, and 9 unknown. The CD19 status of the 32 relapsed patients was based on the ...

CD19 is widely expressed during all phases of B cell development until terminal differentiation into plasma cells. During B cell lymphopoiesis, CD19 surface expression starts during immunoglobulin (Ig) gene rearrangement, which coincides during B lineage commitment from hematopoietic stem cell. [8] Throughout development, the surface density of CD19 is highly regulated. [11]